There are potentially effective treatments for acute myeloid leukemia (AML), but they only work in 20 to 40 percent of cases. In a paper published today in Leukemia, a Nature journal, a UT Health Science Center researcher has pinpointed a protein that could play a key, previously unknown role in the development of pediatric AML — promising new information in the quest to treat and cure childhood leukemias.
AML starts at the point when cells mature into different kinds of blood cells. In AML, the cancerous cells grow and proliferate in an abnormal way, and they fail to develop, or differentiate, into normal functioning white blood cells. Also, high levels of a protein called WTAP contribute to abnormal cell behavior, observed Sanjay Bansal, Ph.D., a researcher at the Greehey Children's Cancer Research Center at The University of Texas Health Science Center at San Antonio.
Dr. Bansal and his team, working with leukemia cells, used a laboratory technique to "knock down" WTAP expression in AML cells. What resulted was, in the research world, a resounding success.
"Knocking down this protein, WTAP, greatly suppressed proliferation and induced differentiation," said Hima Bansal, Ph.D., senior research associate at the Health Science Center and lead author of the paper. "It took care of both problems."
But they needed to understand how WTAP levels get so high in AML in the first place.
The researchers turned to another protein called Hsp90, a so-called "molecular chaperone" that helps stabilize more than 200 other proteins, known as Hsp90 "clients".
"When we suppressed Hsp90, we reduced WTAP," Dr. Bansal said. "So we have discovered two things: WTAP's role in AML and the mechanism underlying its overexpression."
Many of Hsp90's other client proteins are known targets in oncology, and "WTAP joins the list," Dr. Bansal said.
This discovery could open the door to more effective therapies for children and adults with newly diagnosed AML or for patients who have failed currently available treatments.
For current news from the UT Health Science Center, please visit our news release website or follow us on Twitter @uthscsa.
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration.
HKUST researchers discover ways to regenerate corticospinal tract axons
06.07.2015 | Hong Kong University of Science and Technology
Southampton researchers go with the flow to help protect endangered European eel
06.07.2015 | University of Southampton
Wind turbines could be installed under some of the biggest bridges on the road network to produce electricity. So it is confirmed by calculations carried out by a European researchers team, that have taken a viaduct in the Canary Islands as a reference. This concept could be applied in heavily built-up territories or natural areas with new constructions limitations.
The Juncal Viaduct, in Gran Canaria, has served as a reference for Spanish and British researchers to verify that the wind blowing between the pillars on this...
New technique combines electron microscopy and synchrotron X-rays to track chemical reactions under real operating conditions
A new technique pioneered at the U.S. Department of Energy's Brookhaven National Laboratory reveals atomic-scale changes during catalytic reactions in real...
Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and a half billion years ago.
Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and...
A team of scientists including PhD student Friedrich Schuler from the Laboratory of MEMS Applications at the Department of Microsystems Engineering (IMTEK) of...
The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of...
25.06.2015 | Event News
16.06.2015 | Event News
11.06.2015 | Event News
06.07.2015 | Power and Electrical Engineering
06.07.2015 | Press release
06.07.2015 | Physics and Astronomy